Evasc Neurovascular’s eClips Device Approved in French Forfait Innovation Program

February 23, 2021—Evasc Neurovascular announced its successful application to France’s Ministry of Health (Haute Autorité de la Santé) Forfait Innovation (FI) program for the company’s eClips device. The application is published in the French government’s official journal.

The company advised that the French FI program grants clinical trial funding to evaluate CE Mark–approved devices that are deemed to be truly innovative (not simply incremental developments) and offer significant clinical benefit thereby filling an unmet medical need.

The funded amount of €2.76 million covers hospital costs of a 119-patient trial of the Evasc eClips device against optimal performance criteria.

According to the company, eClips is a nontubular endovascular device currently targeted for use in challenging wide-neck bifurcations, using technology designed to treat 95% of cerebral aneurysm cases. The eClips’ design provides coil retention and flow diversion at the neck. Additionally, the device avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while leaving side branches unencumbered and providing a platform for endothelial growth across the bifurcation neck.

Donald Ricci, MD, who is CEO of Evasc Neurovascular, commented in the company's announcement, “We are pleased to have confirmation by an influential and independent third party, the French Ministry of Health, that eClips represents an innovation in the treatment of intracranial bifurcation aneurysms, a consistent message in our presentations, publications, and discussions with neurointerventionalists over the past few years.”

Evasc Neurovascular, a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms, is headquartered in Vancouver, Canada.